Research and Markets: Hemophilia A and B - Japan Drug Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/76hhfw/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - Japan Drug Forecast and Market Analysis to 2022" report to their offering.

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitive Assessment

5.3 Product Profiles - Major Brands, Hemophilia A

5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)

5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant))

5.3.3 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)

5.4 Product Profiles - Hemophilia B

5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant])

5.4.2 Rixubis (BAX-326)

5.5 Product Profiles - Hemophilia A and B with Inhibitors

5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant])

6 Opportunity and Unmet Need

6.1 Overview

6.2 Opportunities Analysis

6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections

6.2.2 Lower-Cost Recombinant Replacement Therapies

6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients

6.2.4 More Convenient Drug Administration

6.2.5 Oral Formulation of Recombinant Replacement Therapies

6.3 Unmet Needs Gap Analysis

6.3.1 Long-Acting FVIII Replacement Therapies

6.3.2 Gene Therapy Treatments for Hemophilia A and B

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development - Hemophilia A

7.2.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein)

7.2.2 BAY 94-9027 (octocog alfa)

7.2.3 BAX-855

7.2.4 Novoeight (turoctocog alfa; NN7008)

7.2.5 N8-GP (NN7088)

7.2.6 CSL-627 (rFVIII-SC)

7.3 Promising Drugs in Clinical Development - Hemophilia B

7.3.1 Alprolix (rFIXFc)

7.3.2 CSL-654 (rIX-FP)

7.3.3 N9-GP (NN-7999)

7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors

7.4.1 BAX-817 (rFVIIa BI)

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/76hhfw/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals